Compare Oxford Lane Capital Corp (OXLC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oxford Lane Capital Corp vs Zimmer Biomet Holdings Inc — how do they compare? Oxford Lane Capital Corp trades at $9.66 (market cap $946.97M), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $18.05B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 19.1× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (24.84%). Which is the better fit depends on your goals.
| OXLC | ZBH | |
|---|---|---|
Market Cap | $946.97M | $18.05B |
Sector | Financials | Health |
52-Week High | $17.73 | $104.26 |
52-Week Low | $8.15 | $79.58 |
Dividend Yield | 24.84% | 1.01% |
Enterprise Value | — | $25.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $9.61, down 0.52% on the day, with a bullish technical signal from moving averages and ADX indicators. The stock shows mixed fundamentals, with a P/B ratio of 0.92 indicating potential undervaluation, but negative ROE and ROA highlight profitability challenges. Recent quarterly earnings have missed expectations, though the company maintains a regular dividend payout of $0.20 monthly. News highlights include partial debt redemptions and net asset value updates, reflecting ongoing capital management efforts.
The outlook for OXLC is cautious due to inconsistent earnings and negative returns on equity, but the deep discount to book value and high dividend yield may attract income-focused investors. Key risks include sustained profitability issues and reliance on financing activities for cash flow, while analyst sentiment is divided with a 50% buy rating. Investors should weigh the high yield against fundamental weaknesses and market volatility.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
